All Dr David Soergel articles
-
NewsNovartis nets potential first-in-class medicine in new cardiovascular acquisition
The potentially multi-billion-dollar deal strengths Novartisā late-stage pipeline for cardiovascular therapies, signalling advancement of novel treatments for heart disease.
-
NewsNovartis releases new data for innovative rare kidney disease treatment
Data from the pre-specified interim analysis of FabhaltaĀ® (iptacopan) indicate a statistically significant reduction in proteinuria reduction.
-
NewsNovartis releases data for potentially āpractice-changing" PNH medicine
Iptacopan achieved "improvement of anaemia never seen before with anti-C5sā in paroxysmal nocturnal haemoglobinuria, showed Novartis data presented at 2023 EBMT.


